Loading ...
one waycan influencewhether a person gets type 2 Type 2 Diabetes Medications With Cardiovascular Benefits
the associated genetic variantscontributeto adverse cardiac outcomes in type 2 diabetes
Liraglutide , a GLP-1 receptor agonistpreventscardiovascular outcomes in patients with type 2 diabetes
that another trial taking place in the United Kingdom , the Glucose Lowering in Non - diabetic Hyperglycaemia Trial ( GLINT ) , is examiningpreventscardiovascular outcomes in people at high risk for type 2 diabetes
Genetic predisposition aside , you can tryto preventtype 2 diabetes through regular cardiovascular exercise
a class of medicationsledto potentially harmful cardiovascular outcomes when used to treat type 2 diabetes
the gradual but cumulatively important improvements in multimodal managementresultingin better cardiovascular outcomes in type 2 diabetes
parental family history ( FH ) of diabetesinfluencescardiovascular outcomes in type 2 diabetes
to life - threatening complications , including wad red , amputation , kidney unsuccessful person and strokecan leadto life - threatening complications , including wad red , amputation , kidney unsuccessful person and stroke
less weight gain and less frequent hypoglycemia than NPH insulin ... even combined with the use of rapid - acting injections of meal insulincausesless weight gain and less frequent hypoglycemia than NPH insulin ... even combined with the use of rapid - acting injections of meal insulin
in significant improvements in blood glucose ( A1C ) levels for those patients and that those results held true even when patients stopped taking other blood - sugar - lowering medications that they had been using simultaneouslyresultedin significant improvements in blood glucose ( A1C ) levels for those patients and that those results held true even when patients stopped taking other blood - sugar - lowering medications that they had been using simultaneously
to statistically significant and sustained reductions in blood sugar and weight in African - Americans with Type 2 diabetes ... as compared with glimepiride , a commonly prescribed diabetes treatmentleadsto statistically significant and sustained reductions in blood sugar and weight in African - Americans with Type 2 diabetes ... as compared with glimepiride , a commonly prescribed diabetes treatment
the decision - making process for selecting a second glucose - lowering agent after metformin in type 2 diabetesmay influencethe decision - making process for selecting a second glucose - lowering agent after metformin in type 2 diabetes
in or contribute to secondary complications of diabetes ( 8 , 29 , 52resultin or contribute to secondary complications of diabetes ( 8 , 29 , 52
to life - threatening complications , including ... Think of momentum as a toolcan leadto life - threatening complications , including ... Think of momentum as a tool
more than anything ... in premature cardiovascular death and morbidity ... Diabetic Medicineresultsmore than anything ... in premature cardiovascular death and morbidity ... Diabetic Medicine
The trial(passive) was designed specificallyThe trial
up a marketing clash with Eli Lillysettingup a marketing clash with Eli Lilly